Ilaris (canakinumab) for injection
TRIKAFTA is a prescription medicine used for the treatment of Periodic fever syndromes, Cryopyrin-associated periodic syndromes, Tumour necrosis factor receptor associated periodic syndrome (TRAPS), Hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD), Familial Mediterranean fever (FMF), Still’s disease, Gouty arthritis. Brand name: Ilaris 150 mg powder for solution for injection
Home | canakinumab for injection
Submit a request to access drug used to treat, diagnose or prevent serious or life-threatening conditions.We’ll get back to you within 1 business days!
For Indian Patient Enquiry under NPP.
Ilaris 150 mg powder for solution for injection
Canakinumab may help to lessen the symptoms, such as rash, joint/muscle pain, fever, eye redness, and tiredness. Canakinumab is also used to treat a type of rheumatoid arthritis in children (systemic juvenile idiopathic arthritis-SJIA), as well as Still's Disease in adults.
Ilaris is a medicine for treating the following inflammatory conditions:
4 types of periodic fever syndromes (diseases marked by recurring inflammation and fever) in adults and children aged 2 and above:
cryopyrin-associated periodic syndromes (CAPS);
tumour necrosis factor receptor associated periodic syndrome (TRAPS);
hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD);
familial mediterranean fever (FMF);
Still’s disease, a rare disease causing inflammation of joints as well as rash and fever (in adults and children aged 2 and above);
Gouty arthritis, painful inflammation of the joints caused by deposit of urate crystals (in adults).
Ilaris contains the active substance canakinumab.
Canakinumab was approved for the treatment of cryopyrin-associated periodic syndromes (CAPS) by the U.S. Food and Drug Administration (FDA) in June 2009, and by the European Medicines Agency (EMA) in October 2009. CAPS is a spectrum of autoinflammatory syndromes including Familial Cold Autoinflammatory Syndrome (FCAS), Muckle–Wells syndrome (MWS), and Neonatal-Onset Multisystem Inflammatory Disease (NOMID).
In September 2016, the FDA approved the use of canakinumab for three additional rare and serious auto-inflammatory diseases: tumor necrosis factor receptor associated periodic syndrome (TRAPS), hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD), and familial mediterranean fever (FMF).
In June 2020, canakinumab was approved in the United States for the indication to treat active Still’s disease, including adult-onset Still’s disease.
In the European Union, canakinumab is indicated for autoinflammatory periodic fever syndromes, cryopyrin-associated periodic syndromes (CAPS), tumour necrosis factor receptor associated periodic syndrome (TRAPS), hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD), familial Mediterranean fever (FMF), Still’s disease, and gouty arthritis.
In August 2023, the FDA expanded coverage to cover the treatment of gout flares.
Drug (Brand / Generic): Ilaris / canakinumab
Current Indications: diseases marked by recurring inflammation and fever
Marketed by:: Novartis Europharm Limited
Approval Date: 23/10/2009
Dosage forms and strengths of Ilaris 150 mg powder for solution for injection
One vial contains 150 mg of canakinumab.
Find Reference Updates
Alleviare Life Sciences
Alleviare Life Sciences Pvt. Ltd. (India) serves as a facilitator for medical and pharmaceutical products, commencing its operations in 2005. Headquartered in Delhi, India, Alleviare operates nationwide, providing a range of comprehensive services to patients, doctors, hospitals, and government healthcare facilities.
Our specialization lies in facilitating access to medicines, leveraging our expertise in sourcing and providing documentation assistance for programs such as Named Patient Program, Managed Access Program, and Early Access Program. We take pride in ensuring smooth and efficient access to medications for those who require them.
Alleviare India is certified pharmaceutical facilitator / supplier /importer based in india. They are also who GDP certified. One of the pharmaceutical products they offer is “ Ilaris (canakinumab) for injection ”. Confirmation of the order for Ilaris (canakinumab) for injection will be subject to the submission of a valid doctor’s prescription and, if applicable, an import permit.
Get Access to Treatment – Ilaris
We have delivered medicines to following cities in India – Ahmedabad, Aizawal, Aurangabad, Barshi, Bengaluru, Bhopal, Cachar, Chennai, Dibrugarh, Hyderabad, Karungapally, Kohima, Kollam, Kolkata, Mumbai, Meghalaya, Mizoram, Sikkim, Nagpur, New Delhi, Pondichery, Pune, Punjab, Thirunananthapuram, Tripura, Wardha.